LifeVantage Corporation reports developments for a health and wellness company built around nutrigenomics, dietary supplements, skin and hair care products, nootropic energy drink mixes, and pet supplements. Its product line includes Protandim, TrueScience Liquid Collagen, MindBody GLP-1 System, LoveBiome P84, AXIO, TrueScience skin and hair care products, and Petandim, sold through independent Consultants to customers.
Company news commonly covers quarterly results, regional sales trends, product innovation, patents tied to cellular-signaling supplement compositions, consultant events and training, international market expansion, executive leadership changes, share repurchases, and cash dividends. Updates also describe capital allocation and the company’s direct-selling business model.
LifeVantage Corporation (Nasdaq: LFVN) will announce its Q1 financial results for the period ending September 30, 2022, on November 2, 2022, after market close. The company will host a conference call for investors at 2:30 p.m. MT (4:30 p.m. ET) on the same day. Interested parties can join the call via U.S. (855) 327-6837 or international (631) 891-4304. A replay will be available until November 9, 2022. Additionally, a live webcast will be accessible on their Investor Relations website, archived for 30 days.
LifeVantage Corporation (Nasdaq: LFVN) has announced a quarterly cash dividend of $0.03 per share, scheduled for payment on September 15, 2022, to stockholders on record as of September 2, 2022. This decision highlights the company's commitment to returning value to its shareholders. LifeVantage specializes in nutrigenomics and offers a range of products including dietary supplements and skin care solutions, while continuously focusing on innovation and growth in this sector.
LifeVantage Corporation (LFVN) reported its fourth-quarter and full-year results for fiscal 2022, revealing a 7.0% revenue decline to $50.9 million in Q4 and a 6.3% drop to $206.4 million for the full year. Active accounts decreased 8.2% to 156,000. The company experienced a net loss of $1.4 million ($0.11 per diluted share) in Q4, compared to a net income of $4.9 million ($0.35 per diluted share) in the previous year. Adjusted EBITDA was $1.7 million in Q4, significantly down from $6.6 million a year earlier. Fiscal 2023 guidance suggests revenue will range from $200 million to $212 million.
LifeVantage Corporation (Nasdaq: LFVN) will release its financial results for the fourth quarter and full fiscal year ending June 30, 2022, on August 23, 2022, after market close. A conference call for investors is scheduled at 2:30 PM MT (4:30 PM ET) on the same day. Investors can participate via phone or listen to a live webcast, with archived access available for 30 days. LifeVantage specializes in nutrigenomics, including dietary supplements and health products like Protandim® and Petandim®.
LifeVantage Corporation (Nasdaq: LFVN) hosted Activate 2022, attracting over 6,000 distributors, marking a strong return to in-person gatherings post-pandemic. The event unveiled TrueScience® Liquid Collagen, featuring a rare Ruby Red Quinoa Extract, which enhances collagen synthesis by 42% and increases antioxidant levels by up to 202%. This product aims to differentiate LifeVantage in the nutrigenomics space by activating natural collagen production.
LifeVantage Corporation (Nasdaq: LFVN) has announced a new quarterly cash dividend of $0.03 per share, set to be paid on May 31, 2022. Shareholders of record as of May 17, 2022 will be eligible for this dividend. The company is noted for its nutrigenomics focus, providing a range of health products including dietary supplements and wellness solutions. This dividend initiation is a significant move, indicating the company's commitment to returning value to its shareholders.
LifeVantage Corporation (Nasdaq: LFVN) reported Q3 FY2022 results with revenues of $50.0 million, a 3.0% year-over-year decline. Total active accounts decreased by 6.5% to 157,000. Earnings per diluted share fell to $0.09 from $0.12 a year ago. The company announced a quarterly dividend of $0.03 per share. Adjusted EBITDA decreased 29.2% to $3.4 million. Fiscal 2022 revenue guidance was lowered to $204-$207 million from $212-$220 million, while adjusted EBITDA guidance was also reduced to $15 million from $18-$20 million.
LifeVantage Corporation (Nasdaq: LFVN) will release its financial results for the third quarter ending March 31, 2022, on May 3, 2022, after market close. A conference call for investors will take place at 2:30 p.m. MT (4:30 p.m. ET) on the same day. Interested participants can join via phone or a live webcast, which will also be available for replay until May 10, 2022. LifeVantage specializes in nutrigenomics, offering products like Protandim® and other dietary supplements aimed at promoting health and wellness.
LifeVantage Corporation (Nasdaq: LFVN) announced the appointment of Cindy Latham to its Board of Directors, bringing over 30 years of experience in global marketing and product development in the direct selling sector. Chairman Garry Mauro applauded her proven leadership and industry expertise, indicating a positive outlook for company growth. Latham expressed her commitment to leveraging LifeVantage's brand strength to develop new strategies. Her past roles include Chief Marketing Officer at Plexus Worldwide and Senior Vice President at Shaklee Corporation.
LifeVantage Corporation (Nasdaq: LFVN) reported Q2 fiscal 2022 results, with revenue of $52.2 million, down 11.6% YoY and 1.9% sequentially. Active accounts fell 6.3% to 163,000, driven by a 17.1% drop in the Americas. Earnings per diluted share were $0.01, compared to $0.26 last year, while adjusted EBITDA decreased 71.6% to $1.9 million. The company repurchased 0.5 million shares for $3.2 million and ended the quarter with $20.2 million in cash and no debt. Guidance for fiscal 2022 has been lowered, anticipating revenues of $212-$220 million.